GSK plc

NYSE:GSK

Drug Manufacturers - General

Healthcare
$48.58 -2.56%

-$1.34 today

Market cap
$97.53B
Beta
0.29
P/E (TTM)
13.3
EPS (TTM)
$1.45
Dividend yield
3.48%
52W Low $35.45High $61.70

Volume 2.02M

Average 4.07M

GSK Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

GSK plcNYSE: GSK

Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026

Cash & equivalents falls 37.4% from a year ago

Cash & equivalents stood at £3.09B at the end of Q2 FY2026, down 37.4% from a year earlier and down 32.0% from the prior quarter. Over 3 fiscal years it compounded at -3.1% a year.

Context

  • Cash & equivalents amounted to 5.0% of total assets at the end of Q2 FY2026, down 1.0 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -37.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
£3.09B-32.0% QoQ
Last fiscal yearDec 2025
£3.39B-8.2% YoY
Year agoJun 2025
£4.93B-37.4% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-37.4%——
1 year-8.2%——
3-year CAGR-3.1%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

GBP · from the balance sheet

Latest · FY2025
3.39B GBP
Year-over-year change
-8.2%
4-year CAGR
-12.5%

Cash & Equivalents vs competitors

How GSK compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -37.4% is the 8th highest of 10, against a peer median of -2.7%.
  • Cash & equivalents amounts to 5.0% of total assets for GSK, versus a peer median of 6.2%.
GSK Competitors
Cash & Equivalents for GSK and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NVONovo Nordisk A/SJun 2026DKK 44.48B DKK+141.3%+27.9%7.5%
JNJJohnson & JohnsonSep 2026$16.91B USD-7.2%+15.2%8.6%
AMGNAmgen Inc.Jun 2026$13.99B USD+74.3%+6.2%14.6%
LLYEli Lilly and CompanyJun 2026$8.89B USD+163.3%+51.3%6.2%
AZNAstraZeneca PLCSep 2026$7.92B USD-2.7%-2.5%6.6%
NVSNovartis AGJun 2026$7.62B USD+14.4%+15.0%6.2%
MRKMerck & Co., Inc.Jun 2026$6.85B USD-14.5%+4.7%5.3%
SNYSanofiJun 2026€6.35B EUR-58.7%-15.6%4.9%
GSKGSK plcJun 2026£3.09B GBP-37.4%-3.1%5.0%
PFEPfizer Inc.Jun 2026$976M USD-40.4%+40.0%0.5%
Peer median (excluding GSK) —-2.7%+15.0%6.2%

Competitors are the stored peer set for GSK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

GBP
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents5.79B3.72B3.74B3.69B3.39B
Short-term Investments82.62M4.15B2.86B21M8.98M
Net Receivables10.88B6.22B9.44B6B7.75B
Inventory7.83B5.15B7.01B5.67B5.91B
Other Current Assets284.44M1.1B262.61M1.23B420.26M
Total Current Assets25.29B20.77B23.77B17B17.48B
Property, Plant & Equipment (Net)14.45B9.62B12.69B10.07B10.03B
Goodwill14.29B7.05B8.68B6.98B7.01B
Intangible Assets40.74B14.32B18.83B15.52B16.72B
Long-term Investments4.29B(2.61B)2.73B1.21B1.12B
Tax Assets7.07B5.66B7.71B6.76B6.51B
Other Non-current Assets1B5.35B808.22M1.93B2.14B
Total Non-current Assets81.85B39.38B51.45B42.47B43.53B
Total Assets107.14B60.15B75.22B59.46B61.01B
Account Payables6.14B3.87B4.74B3.46B15.35B
Short-term Debt4.88B3.79B3.59B2.18B3.01B
Tax Payables489M471M500M703M0
Deferred Revenue415.82M0283.01M00
Other Current Liabilities17.97B14.1B15.25B14.76B2.5B
Total Current Liabilities32.06B22.81B26.86B21.7B21.35B
Long-term Debt26.76B16.19B18.04B13.7B14.68B
Deferred Tax Liabilities4.82B289M396.46M382M290.49M
Deferred Revenue (Non-current)115.13M83M323.8M165M0
Other Non-current Liabilities13.38B9.83B11.95B9.5B8.69B
Total Non-current Liabilities46.17B27.24B32.05B24.68B23.66B
Total Liabilities78.23B50.05B58.91B46.38B45.02B
Common Stock1.82B1.35B1.72B1.35B1.35B
Retained Earnings13.26B4.36B9.23B7.8B10.19B
Accumulated OCI869.56M02.04B00
Other Stockholders Equity01.45B01.05B1.32B
Minority Interest8.52B(502M)(703.69M)(585M)(420.26M)
Total Equity28.91B10.1B16.31B13.09B15.93B
Total Debt32.74B20.99B22.97B16.99B17.69B
Net Debt26.95B17.26B19.23B13.29B14.3B

GSK plc

NYSE:GSK

Intrinsic Alpha fair value

Locked

Current Price

$48.58

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.